手术治疗的非典型脑膜瘤早期进展的预测因素
本研究纳入2007至2014年间在三家区域转诊中心治疗的220例成人WHO II级脑膜瘤患者,评估影像与病理特征对早期进展的预测价值。37例(16.8%)在术后24个月内进展,次全切除、矢状窦旁/大脑镰旁位置、瘤周水肿及核分裂指数>7为独立预测因素,辅助放疗与早期复发呈负相关;早期复发者末次随访时预后良好(mRS 0-1)的比例显著更低。
要点
- 220例中37例(16.8%)在术后24个月内进展。
- 次全切除、矢状窦旁/大脑镰旁位置、瘤周水肿、核分裂指数>7为早期进展的独立预测因素。
- 早期复发患者末次随访时mRS 0-1的比例显著更低。
核心结论
- 非典型脑膜瘤为异质性肿瘤,16.8%的患者在术后24个月内复发。
- 残留肿瘤、矢状窦旁/大脑镰旁位置、瘤周水肿及核分裂指数>7均与早期复发独立相关。
- 由于本队列中辅助放疗未按方案统一实施,关于WHO II级脑膜瘤放疗获益的任何结论应谨慎看待。
- 早期复发患者神经功能预后更差。
- 组织学和影像特征具有一定预后价值,但仍需进一步分子表征以辅助临床决策。
研究设计与样本
- 纳入2007至2014年间在三家区域转诊中心治疗的成人WHO II级脑膜瘤患者。
- 评估MRI与病理特征;全切除(GTR)定义为Simpson 1-3级。
- 复发分为早期与晚期(≤24个月 vs >24个月)。
主要发现
- 220例中37例(16.8%)在术后24个月内进展。
- 早期进展的独立预测因素为次全切除(STR)(p=0.005)、矢状窦旁/大脑镰旁位置(p=0.015)、瘤周水肿(p=0.027)及核分裂指数(MI)>7(p=0.007)。
- 辅助放疗与早期复发呈负相关(p=0.046)。
- 有残留肿瘤的患者中32%接受辅助放疗,全切除后26%接受辅助放疗。
- 早期复发患者末次随访时预后良好(mRS 0-1)的比例显著更低(p=0.001)。
关键数值与推荐
- 全切除(GTR)定义为Simpson 1-3级。
- 复发分为早期与晚期(≤24个月 vs >24个月)。
- 核分裂指数(MI)>7为早期进展的独立预测因素(p=0.007)。
临床怎么用
- 作者认为,由于本队列中辅助放疗未按方案统一实施,关于WHO II级脑膜瘤放疗获益的任何结论应谨慎看待。
- 作者认为,组织学和影像特征提供一定预后价值,但仍需进一步分子表征以辅助临床决策。
局限性
- 本队列中辅助放疗未按方案统一实施,关于WHO II级脑膜瘤放疗获益的任何结论应谨慎看待。
- 仍需进一步分子表征非典型脑膜瘤以辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical behaviour of atypical meningiomas is not uniform. While, as a group, they exhibit a high recurrence rate, some pursue a more benign course, whereas others progress early. We aim to investigate the imaging and pathological factors that predict risk of early tumour progression and to determine whether early progression is related to outcome. METHODS: Adult patients with WHO grade II meningioma treated in three regional referral centres between 2007 and 2014 were included. MRI and pathology characteristics were assessed. Gross total resection (GTR) was defined as Simpson 1-3. Recurrence was classified into early and late (≤ 24 vs. > 24 months). RESULTS: Among the 220 cases, 37 (16.8%) patients progressed within 24 months of operation. Independent predictors of early progression were subtotal resection (STR) (p = 0.005), parafalcine/parasagittal location (p = 0.015), peritumoural oedema (p = 0.027) and mitotic index (MI) > 7 (p = 0.007). Adjuvant radiotherapy was negatively associated with early recurrence (p = 0.046). Thirty-two per cent of patients with residual tumour and 26% after GTR received adjuvant radiotherapy. There was a significantly lower proportion of favourable outcomes at last follow-up (mRS 0-1) in patients with early recurrence (p = 0.001). CONCLUSIONS: Atypical meningiomas are a heterogeneous group of tumours with 16.8% patients having recurrence within 24 months of surgery. Residual tumour, parafalcine/parasagittal location, peritumoural oedema and a MI > 7 were all independently associated with early recurrence. As administration of adjuvant radiotherapy was not protocolised in this cohort, any conclusions about benefits of irradiation of WHO grade II meningiomas should be viewed with caution. Patients with early recurrence had worse neurological outcome. While histological and imaging characteristics provide some prognostic value, further molecular characterisation of atypical meningiomas is warranted to aid clinical decision making.
引用
- Budohoski KP, Clerkin J, Millward CP, et al. Predictors of early progression of surgically treated atypical meningiomas. Acta Neurochir (Wien). 2018. PMID: 29961125. doi:10.1007/s00701-018-3593-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。